Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-28
2007-08-28
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S008100, C530S324000, C530S350000, C530S395000, C530S397000, C530S399000, C530S402000, C435S069400
Reexamination Certificate
active
10409807
ABSTRACT:
The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5252714 (1993-10-01), Harris et al.
patent: 5641663 (1997-06-01), Garvin et al.
patent: 5824784 (1998-10-01), Kinstler et al.
patent: 5834594 (1998-11-01), Hakimi et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6583272 (2003-06-01), Bailon
patent: 6586398 (2003-07-01), Kinstler et al.
patent: 2204640 (2001-01-01), None
patent: WO95/05465 (1995-02-01), None
patent: WO98/05363 (1998-02-01), None
Delagado etal., Critical Reviews in Therapeutic Drug Carrier Systems, vol. 9, No. 3,4, pp. 249-304, 1992.
MacDougall, et al., “Comparison of the Pharmacokinetics of Novel Erythropoiesis Stimulating Protein (NESP) and Epoetin Alfa (rhEPO) in Dialysis Patients”,Journal of the American Society of Nephrology, vol. 8, pp. 268A, (1997).
Egrie, et al., “Novel Erythropoiesis Stimulating Protein (NESP) has a longer Serum Half-life and greaterin vivoBiological Activity Than Recombinant Human Erythropoietin (rHuEPO)”,Blood, vol. 90, pp. 56a, (1997).
MacDougall et al., J. Am. Soc. Nephrol., “Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients” 10, 2392-2395 (1999).
Nandini V. Katre, Advanced Drug Delivery Reviews, “The Conjugation of Proteins with Polyethylene Glycol and other Polymers, Altering Properties of Proteins to Enhance Their Therapeutic Potential” 10, 91-114 (1993).
Nucci, et al., Advanced Drug Delivery Reviews, “The Therapeutic Value of Poly(ethylene glycol)-modified Proteins” 133-151 (1991).
Boone Thomas
Freeman Aimee
Gegg Colin
Kinstler Olaf
Amgen Inc.
Hsi Petrina S.
Mohamed Abdel A.
Weber Jon
LandOfFree
Chemically modified novel erythropoietin stimulating protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemically modified novel erythropoietin stimulating protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically modified novel erythropoietin stimulating protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3871711